Real-world clinical utility (effectiveness) of omalizumab as add-on therapy in patient with difficult-to-treat severe allergic asthma
Background: Severe allergic asthma (SAA) requires high-dose inhaled corticosteroids and additional medications. It poses a substantial health and financial burden. Omalizumab, an antibody that targets IgE, has improved symptoms and quality of life in severe allergic asthma (SAA) patients. Its impact...
Shranjeno v:
| Principais autores: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2025-01-01
|
| Serija: | Current Research in Pharmacology and Drug Discovery |
| Teme: | |
| Online dostop: | http://www.sciencedirect.com/science/article/pii/S2590257125000069 |
| Oznake: |
Brez oznak, prvi označite!
|